ATE133961T1 - Insulinanaloge - Google Patents

Insulinanaloge

Info

Publication number: ATE133961T1
Authority: AT; Austria
Prior art keywords: absent; lys; threonine; arg; aspartic acid
Prior art date: 1989-02-09

Application number

AT90301224T

Other languages

English (en)

Inventor

Ronald Eugene Chance

Richard Dennis Dimarchi

Bruce Hill Frank

James Edwin Shields

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-09

Filing date

1990-02-06

Publication date

1996-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE133961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-02-06 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1996-02-15 Application granted granted Critical

1996-02-15 Publication of ATE133961T1 publication Critical patent/ATE133961T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 5
239000004473 Threonine Substances 0.000 abstract 5
235000003704 aspartic acid Nutrition 0.000 abstract 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 5
235000009582 asparagine Nutrition 0.000 abstract 4
229960001230 asparagine Drugs 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
229930182821 L-proline Natural products 0.000 abstract 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
235000004279 alanine Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
229960002429 proline Drugs 0.000 abstract 2
239000004474 valine Substances 0.000 abstract 2
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 abstract 1
JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 1
229930182820 D-proline Natural products 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 abstract 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
229940024606 amino acid Drugs 0.000 abstract 1
108010068380 arginylarginine Chemical group 0.000 abstract 1
108010062796 arginyllysine Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
235000004554 glutamine Nutrition 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
108010054155 lysyllysine Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
PMMYEEVYMWASQN-IUYQGCFVSA-N trans-4-hydroxy-D-proline Chemical compound O[C@@H]1CN[C@@H](C(O)=O)C1 PMMYEEVYMWASQN-IUYQGCFVSA-N 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/622—Insulins at least 1 amino acid in D-form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Immunology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Unknown Constitution (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT90301224T 1989-02-09 1990-02-06 Insulinanaloge ATE133961T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30835289A	1989-02-09	1989-02-09
US38820189A	1989-08-04	1989-08-04

Publications (1)

Publication Number	Publication Date
ATE133961T1 true ATE133961T1 (de)	1996-02-15

Family

ID=26976211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90301224T ATE133961T1 (de)	1989-02-09	1990-02-06	Insulinanaloge

Country Status (24)

Country	Link
EP (2)	EP0383472B1 (de)
JP (1)	JPH0822878B2 (de)
KR (1)	KR0169727B1 (de)
CN (2)	CN1034080C (de)
AT (1)	ATE133961T1 (de)
AU (1)	AU630912B2 (de)
BG (1)	BG60769B2 (de)
CA (1)	CA2009579C (de)
CY (1)	CY1911A (de)
DE (3)	DE69033889T2 (de)
DK (2)	DK0383472T3 (de)
ES (2)	ES2083424T3 (de)
FI (1)	FI95915C (de)
GR (1)	GR3019501T3 (de)
HK (1)	HK60296A (de)
HU (2)	HU212679B (de)
IE (1)	IE73251B1 (de)
IL (1)	IL93282A (de)
LU (2)	LU88830I2 (de)
NL (1)	NL960026I2 (de)
NO (2)	NO179587C (de)
NZ (1)	NZ232375A (de)
PT (1)	PT93057B (de)
RU (1)	RU2109749C1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUT56857A (en) *	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
US5716927A (en) *	1988-12-23	1998-02-10	Novo Nordisk A/S	Insulin analogs having a modified B-chain
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
IL102240A0 (en) *	1991-06-21	1993-01-14	Lilly Co Eli	Insulin analogs
GB9316895D0 (en)	1993-08-13	1993-09-29	Guy S And St Thomas Hospitals	Hepatoselective insulin analogues
US6131567A (en) *	1993-01-29	2000-10-17	Aradigm Corporation	Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
EP1607086A1 (de) *	1993-01-29	2005-12-21	Aradigm Corporation	Verfahren zur Verwendung monomeren Insulins als Mittel zur Verbesserung der Reproduzierbarkeit inhalierten Insulins
DK72793D0 (da) *	1993-06-21	1993-06-21	Novo Nordisk As	Nyt produkt
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5504188A (en)	1994-06-16	1996-04-02	Eli Lilly And Company	Preparation of stable zinc insulin analog crystals
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
US5547929A (en)	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5597893A (en)	1994-10-31	1997-01-28	Eli Lilly And Company	Preparation of stable insulin analog crystals
US5693609A (en) *	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
US5646242A (en) *	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
IL118127A0 (en) *	1995-05-05	1996-09-12	Lilly Co Eli	Single chain insulin with high bioactivity
US5631347A (en) *	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
US5700904A (en) *	1995-06-07	1997-12-23	Eli Lilly And Company	Preparation of an acylated protein powder
HU228094B1 (en) *	1996-06-20	2012-10-29	Novo Nordisk As	Insulin preparations containing nacl
PT821006E (pt) *	1996-07-26	2004-09-30	Aventis Pharma Gmbh	Derivados de insulina com ligacao a zinco aumentada
SE520392C2 (sv)	1996-09-27	2003-07-01	Creative Peptides Sweden Ab C	Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
HUP0004169A3 (en)	1997-10-24	2001-06-28	Lilly Co Eli	Insoluble insulin compositions and process for production thereof
CO4970787A1 (es)	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US20010053761A1 (en) *	1998-01-08	2001-12-20	Dimarchi Richard Dennis	Method for administering aspb28-human insulin
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) *	1999-09-08	2003-10-22	中国科学院上海生物化学研究所	重组天然和新型人胰岛素及其制备方法
US7638618B2 (en)	2001-02-20	2009-12-29	Sanofi-Aventis Deutschland Gmbh	Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en)	2001-02-20	2007-04-10	Sanofi-Aventis Deutschland Gmbh	Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
AU2003218635A1 (en) *	2002-05-07	2003-11-11	Novo Nordisk A/S	Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en)	2002-10-29	2007-03-20	Sanofi-Aventis Deutschland Gmbh	Crystals of insulin analogs and processes for their preparation
RU2235776C1 (ru) *	2003-03-17	2004-09-10	Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова РАН	Рекомбинантная плазмидная днк plp-3,1, кодирующая полипептид проинсулина lyspro человека, и штамм бактерий escherichia coli plp-3-1/tg-1-продуцент рекомбинантного проинсулина lyspro
AU2004261353B2 (en)	2003-08-05	2009-12-10	Novo Nordisk A/S	Novel insulin derivatives
ES2472421T3 (es)	2003-08-05	2014-07-01	Novo Nordisk A/S	Nuevos derivados de insulina
JP4800959B2 (ja) *	2003-11-13	2011-10-26	ノヴォノルディスクアー／エス	糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
KR101243648B1 (ko)	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
ES2369895T3 (es)	2003-12-03	2011-12-07	Novo Nordisk A/S	Insulina monocatenaria.
CN101027318B (zh)	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
WO2006082204A1 (en)	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
ES2435522T3 (es)	2005-02-02	2013-12-20	Novo Nordisk A/S	Derivados de insulina
WO2006093222A1 (ja) *	2005-03-02	2006-09-08	Ajinomoto Co., Inc.	インスリンの多量体形成阻害剤
ATE513921T1 (de)	2005-08-16	2011-07-15	Novo Nordisk As	Verfahren zur herstellung reifer insulinpolypeptide
ATE517919T1 (de)	2005-09-14	2011-08-15	Sanofi Aventis Deutschland	Spaltung von insulinvorstufen durch eine trypsinvariante
EP1969004B1 (de)	2005-12-28	2011-08-10	Novo Nordisk A/S	Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
JP5202338B2 (ja)	2006-02-27	2013-06-05	ノボ・ノルデイスク・エー／エス	新規インシュリン誘導体
EP2241327A1 (de)	2006-03-15	2010-10-20	Novo Nordisk A/S	Mischung von Amylin und Insulin
WO2007128815A1 (en)	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
AU2007247109B2 (en)	2006-05-09	2012-03-15	Novo Nordisk A/S	Insulin derivative
CN101541830A (zh)	2006-09-22	2009-09-23	诺沃-诺迪斯克有限公司	蛋白酶抗性的胰岛素类似物
WO2008132224A2 (en)	2007-04-30	2008-11-06	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
AU2008257505B2 (en)	2007-06-01	2013-05-16	Novo Nordisk A/S	Stable non-aqueous pharmaceutical compositions
EP2514406A1 (de)	2007-06-01	2012-10-24	Novo Nordisk A/S	Spontan dispergierbare Vorkonzentrate mit einem Peptidwirkstoff in einem festen oder halbfesten Träger
JP5552046B2 (ja)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	インスリン誘導体を含有する薬学的製剤
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
CN102202683A (zh)	2008-10-30	2011-09-28	诺沃-诺迪斯克有限公司	用少于每日一次的注射频率注射胰岛素来治疗糖尿病
EP2451471A1 (de)	2009-07-06	2012-05-16	Sanofi-Aventis Deutschland GmbH	Langsamwirkende insulinzubereitungen
WO2011003820A1 (de) *	2009-07-06	2011-01-13	Sanofi-Aventis Deutschland Gmbh	Hitze- und schüttelstabile insulinzubereitungen
PH12011502708B1 (en)	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
DK2459171T3 (en)	2009-07-31	2017-09-25	Sanofi Aventis Deutschland	Long-acting insulin composition
KR20120089843A (ko)	2009-07-31	2012-08-14	사노피-아벤티스 도이칠란트 게엠베하	인슐린 링커 접합체를 포함한 프로드럭
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011252127B2 (en)	2010-05-10	2014-02-20	Novo Nordisk A/S	Process for the preparation of insulin-zinc complexes
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
EP2438930A1 (de)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrug mit einem exendinbindenden Konjugat
DK2632478T3 (da)	2010-10-27	2019-10-07	Novo Nordisk As	Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
KR20130139297A (ko)	2010-10-27	2013-12-20	노보 노르디스크 에이/에스	다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료
CN102199206B (zh) *	2011-03-17	2013-03-20	甘李药业股份有限公司	快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2844274B1 (de)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmazeutische zusammensetzung
US20130315891A1 (en)	2012-05-25	2013-11-28	Matthew Charles	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en)	2012-06-04	2013-12-05	Matthew Charles	Human tissue kallikrein 1 glycosylation isoforms
US9867869B2 (en)	2012-12-12	2018-01-16	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
MX360420B (es)	2012-12-19	2018-10-31	Wockhardt Ltd	Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
MX2015006997A (es)	2012-12-26	2015-09-23	Wockhardt Ltd	Composicion farmaceutica.
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AR095986A1 (es) *	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
EP2991672A1 (de)	2013-04-30	2016-03-09	Novo Nordisk A/S	Neuartiges verabreichungsschema
EP3052114A1 (de)	2013-09-30	2016-08-10	Wockhardt Limited	Pharmazeutische zusammensetzung
JP6641280B2 (ja)	2014-01-09	2020-02-05	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
KR20160104726A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
CA2932873A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
JP2017522282A (ja) *	2014-06-10	2017-08-10	カリフォルニアインスティチュートオブテクノロジー	非標準的インスリンおよびそれらの使用
WO2016001862A1 (en)	2014-07-04	2016-01-07	Wockhardt Limited	Extended release formulations of insulins
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
AU2017332408B2 (en) *	2016-09-23	2022-02-10	Hanmi Pharm. Co., Ltd.	Insulin analogs with reduced affinity to insulin receptor and use thereof
EP4265296A3 (de)	2016-09-29	2023-12-20	Arecor Limited	Pharmazeutische zubereitung enthaltend einer insulinverbindung
AU2018230478B2 (en)	2017-03-09	2025-01-23	Diamedica Inc.	Dosage forms of tissue kallikrein 1
GB201707187D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707189D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
GB201707188D0 (en)	2017-05-05	2017-06-21	Arecor Ltd	Novel formulations
JP7465813B2 (ja)	2018-04-04	2024-04-11	アレコルリミテッド	インスリン化合物の送達のための医療用注入ポンプシステム
EP3773474B1 (de)	2018-04-04	2026-01-07	Arecor Limited	Medizinisches infusionspumpensystem zur abgabe einer insulinverbindung
EP3773473B1 (de)	2018-04-04	2026-07-01	Arecor Limited	Medizinisches infusionspumpensystem zur abgabe einer insulinverbindung
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR20200082618A (ko)	2018-12-31	2020-07-08	주식회사 폴루스	인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂
BR112022013009A2 (pt)	2019-12-30	2022-09-06	Gan & Lee Pharmaceuticals Co Ltd	Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
AU2020418207A1 (en)	2019-12-30	2022-08-25	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting GLP-1 compound
GB202004814D0 (en)	2020-04-01	2020-05-13	Arecor Ltd	Novel formulations
WO2023143458A1 (zh)	2022-01-28	2023-08-03	甘李药业股份有限公司	酰化胰岛素

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3101382A1 (de) *	1981-01-17	1982-09-02	Hoechst Ag, 6000 Frankfurt	"verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
US5126249A (en) *	1989-05-09	1992-06-30	Eli Lilly And Company	Enzymatic removal of a protein amino-terminal sequence

1990
- 1990-02-05 IL IL9328290A patent/IL93282A/en not_active IP Right Cessation
- 1990-02-05 PT PT93057A patent/PT93057B/pt active IP Right Grant
- 1990-02-05 NZ NZ232375A patent/NZ232375A/en unknown
- 1990-02-06 CY CY191190A patent/CY1911A/xx unknown
- 1990-02-06 LU LU88830C patent/LU88830I2/fr unknown
- 1990-02-06 DK DK90301224.3T patent/DK0383472T3/da active
- 1990-02-06 EP EP90301224A patent/EP0383472B1/de not_active Expired - Lifetime
- 1990-02-06 ES ES90301224T patent/ES2083424T3/es not_active Expired - Lifetime
- 1990-02-06 AT AT90301224T patent/ATE133961T1/de active
- 1990-02-06 ES ES95200804T patent/ES2170122T3/es not_active Expired - Lifetime
- 1990-02-06 EP EP95200804A patent/EP0678522B1/de not_active Expired - Lifetime
- 1990-02-06 DE DE69033889T patent/DE69033889T2/de not_active Expired - Lifetime
- 1990-02-06 DE DE69025210T patent/DE69025210T2/de not_active Expired - Lifetime
- 1990-02-06 DE DE1990625210 patent/DE19675034I2/de active Active
- 1990-02-06 DK DK95200804T patent/DK0678522T3/da active
- 1990-02-06 LU LU88831C patent/LU88831I2/fr unknown
- 1990-02-07 FI FI900600A patent/FI95915C/fi active IP Right Grant
- 1990-02-07 AU AU49226/90A patent/AU630912B2/en not_active Expired
- 1990-02-07 IE IE44090A patent/IE73251B1/en not_active IP Right Cessation
- 1990-02-08 JP JP2031347A patent/JPH0822878B2/ja not_active Expired - Lifetime
- 1990-02-08 KR KR1019900001498A patent/KR0169727B1/ko not_active Expired - Lifetime
- 1990-02-08 CN CN90101415A patent/CN1034080C/zh not_active Expired - Lifetime
- 1990-02-08 CA CA002009579A patent/CA2009579C/en not_active Expired - Lifetime
- 1990-02-08 NO NO900615A patent/NO179587C/no not_active IP Right Cessation
- 1990-02-08 HU HU90726A patent/HU212679B/hu unknown
1991
- 1991-11-21 RU SU5010208A patent/RU2109749C1/ru active
1994
- 1994-02-25 BG BG098572A patent/BG60769B2/bg unknown
1995
- 1995-06-07 HU HU95P/P00171P patent/HU211276A9/hu unknown
1996
- 1996-04-02 GR GR960400889T patent/GR3019501T3/el unknown
- 1996-04-03 HK HK60296A patent/HK60296A/en not_active IP Right Cessation
- 1996-05-23 CN CN96106635A patent/CN1103602C/zh not_active Ceased
- 1996-10-17 NL NL960026C patent/NL960026I2/nl unknown
- 1996-12-09 NO NO1996013C patent/NO1996013I1/no unknown

Also Published As

Publication number	Publication date
CY1911A (en)	1990-02-06
ES2170122T3 (es)	2002-08-01
NO900615D0 (no)	1990-02-08
HU212679B (en)	1996-09-30
FI95915C (fi)	1996-04-10
CN1034080C (zh)	1997-02-19
CN1103602C (zh)	2003-03-26
JPH02264798A (ja)	1990-10-29
NL960026I1 (nl)	1997-01-06
KR900012627A (ko)	1990-09-01
DE69025210D1 (de)	1996-03-21
RU2109749C1 (ru)	1998-04-27
NO1996013I1 (no)	1996-12-09
HU900726D0 (en)	1990-04-28
IL93282A0 (en)	1990-11-29
NL960026I2 (nl)	1997-05-01
JPH0822878B2 (ja)	1996-03-06
DE19675034I2 (de)	2006-11-16
DE69025210T2 (de)	1996-06-13
GR3019501T3 (en)	1996-07-31
PT93057A (pt)	1990-08-31
EP0678522B1 (de)	2002-01-02
CN1044820A (zh)	1990-08-22
AU4922690A (en)	1990-08-16
AU630912B2 (en)	1992-11-12
CA2009579C (en)	2000-04-11
IE73251B1 (en)	1997-05-21
ES2083424T3 (es)	1996-04-16
LU88831I2 (fr)	1997-01-10
EP0383472B1 (de)	1996-02-07
IL93282A (en)	1995-08-31
HUT57795A (en)	1991-12-30
CA2009579A1 (en)	1990-08-09
DK0383472T3 (da)	1996-05-06
KR0169727B1 (ko)	1999-01-15
NZ232375A (en)	1992-04-28
DE69033889T2 (de)	2002-08-22
NO179587B (no)	1996-07-29
FI95915B (fi)	1995-12-29
PT93057B (pt)	1995-12-29
IE900440L (en)	1990-08-09
EP0383472A2 (de)	1990-08-22
EP0678522A1 (de)	1995-10-25
EP0383472A3 (de)	1991-09-18
FI900600A0 (fi)	1990-02-07
CN1148984A (zh)	1997-05-07
NO900615L (no)	1990-08-10
DK0678522T3 (da)	2002-03-11
DE69033889D1 (de)	2002-02-07
LU88830I2 (fr)	1997-01-06
HU211276A9 (en)	1995-11-28
BG60769B2 (bg)	1996-02-29
NO179587C (no)	1996-11-06
HK60296A (en)	1996-04-12

Publication	Publication Date	Title
NL960026I1 (nl)	1997-01-06	Insuline-analogen.
PE47096A1 (es)	1996-11-12	Analogo, composicion y uso del peptido insulinotropico similar al glucagon
CA2073856A1 (en)	1991-07-25	Glp-1 analogs useful for diabetes treatment
NZ517012A (en)	2003-02-28	Peptides that lower blood glucose levels
ATE99699T1 (de)	1994-01-15	Peptide.
DE69018226D1 (de)	1995-05-04	Markierte polypeptidderivate.
FI925972A0 (fi)	1992-12-31	Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
DK424989A (da)	1990-03-01	Rekombinant, naturlig, draebercelleaktiverende faktor
KR910002899A (ko)	1991-02-26	혈조절 펩타이드
DE69302921D1 (de)	1996-07-11	Neue Peptidderivate, Verfahren zu deren Herstellung und deren Anwendung als Heilmittel
DE60001489D1 (de)	2003-04-03	Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
ES2135389T3 (es)	1999-11-01	Antagonistas de endotelina.
ATE207496T1 (de)	2001-11-15	Neue peptide und nootroper wirkstoff
RU93004930A (ru)	1996-01-27	Днк, соматотропин, плазмиды, рекомбинантные организмы, композиция, способ получения соматотропина, способы стимулирования роста